Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Urticaria | Treatment Algorithms: Claims Data Analysis | Chronic spontaneous urticaria | US | 2023
The drug market for chronic spontaneous urticaria (CSU; previously known as chronic idiopathic urticaria) is dominated by oral medications, including those approved (e.g., first- and second-…
Acute Coronary Syndrome: Secondary Prevention | Treatment Algorithms: Claims Data Analysis | US | 2025
Acute coronary syndrome (ACS)—subtype of coronary artery disease (CAD)—is an umbrella term encompassing ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable…
Alzheimer’s Disease – Special Topics – Special Topics: Caregiver Perspectives on Diagnostics and Leqembi in the Treatment of Alzheimer’s Disease (US)
Eisai / Biogen’s Leqembi (lecanemab) gained accelerated and full FDA approval in 2023 based on positive clinical and biomarker outcomes from the Phase 3 CLARITY-AD trial. With the U.S. CMS…
Autism Spectrum Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Autism Spectrum Disorder (US)
Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder involving significant social, communication, and behavioral challenges. Behavioral and developmental therapies are the…
Major Depressive Disorder | Treatment Algorithms: Claims Data Analysis | US | 2024
Major depressive disorder (MDD) is a highly drug-treated condition that uses an array of drug classes, including, but not limited to, selective serotonin reuptake inhibitors (SSRIs), selective…
